Institution

University Hospital Ulm

Ulm, GermanyWebsite

Also known as: Universitätsklinikum Ulm

403running trials
172closed trials
26,617publications (OpenAlex)

Running trials

Not yet recruiting
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma
2025-522563-15-00· Phase 2/3· AbbVie Deutschland GmbH & Co. KG· Source
Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Nationwide Children's Hospital· Source
Not yet recruiting
Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care
NCT07699640· Heinrich-Heine University, Duesseldorf· Source
Not yet recruiting
Post-intervention dual antiplatelet therapy for mild stroke
2026-525681-22-00· Phase 3· Technische Universitaet Dresden· Source
Not yet recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188· Phase 3· AbbVie· Source
Recruiting
SIL204-SL Treatment for Locally Advanced Pancreatic Cancer
2025-525157-39-00· Phase 2/3· Silexion Therapeutics Ltd.· Source
Not yet recruiting
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
NCT07923383· Phase 1· Sanofi· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
NCT07825064· Phase 2· Hoffmann-La Roche· Source
Recruiting
Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
NCT07789574· Phase 2· Thomas Ernst, Prof. Dr. med.· Source
Not yet recruiting
Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
NCT07897760· Otto Bock Healthcare Products GmbH· Source
Recruiting
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source
Not yet recruiting
Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source
Recruiting
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
2025-525030-57-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
NCT07004413· Phase 3· Charite University, Berlin, Germany· Source
Recruiting
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
2025-522707-26-00· Phase 1· Novartis Pharma AG· Source
Not yet recruiting
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
NCT07719348· Phase 1/2· Servier· Source
Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· Phase 3· AstraZeneca· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Incyte Corp.· Source
Not yet recruiting
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Recruiting
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma
NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
2026-525234-39-00· Phase 1· Janssen Cilag International· Source
Recruiting
Registry for Duchenne and Becker Muscular Dystrophy
NCT07402122· Dr. Andreas Ziegler· Source
Recruiting
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108· Phase 3· Prilenia· Source
Recruiting
A Randomized Phase 1 / 2 Trial Aiming to Restore UNC13A Function in People living with ALS: FUNCtion ALS
2025-523111-11-00· Phase 1/2· Trace Neuroscience Inc.· Source
Not yet recruiting
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· Phase 3· University of Heidelberg Medical Center· Source
Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source
Recruiting
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source
Recruiting
ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
NCT06801899· Insel Gruppe AG, University Hospital Bern· Source
Recruiting
PREFer
NCT06916416· Phase 2· University Of Cologne· Source
Recruiting
A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease
2025-522001-38-00· Phase 2· Mirador Therapeutics Inc.· Source
Not yet recruiting
Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH).
2025-523672-23-00· Phase 2· UroTrials GmbH· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07571174· Phase 1· Eli Lilly and Company· Source
Recruiting
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07571200· Phase 1· Eli Lilly and Company· Source
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)
2025-524002-16-00· Phase 3· Ferrer Internacional S.A.· Source
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
NCT07531927· Okuvision GmbH· Source
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073· Phase 2· Eli Lilly and Company· Source
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099· Phase 2· Eli Lilly and Company· Source
Recruiting
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
NCT07221669· Phase 3· Biogen· Source
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995· Phase 3· BioNTech SE· Source
Recruiting
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
NCT06792994· German CLL Study Group· Source
Recruiting
Improved Management of Patients With Recent-Onset Stable Chest Pain
NCT07476040· Philipps University Marburg· Source
Recruiting
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study
2025-522338-30-00· Phase 2· Eli Lilly & Co.· Source
Recruiting
Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA
NCT07436195· University of Ulm· Source

Showing 50 of 403.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers27 recruiting
Colorectal cancer18 recruiting
Pancreatic cancer17 recruiting
Acute myeloid leukaemia16 recruiting
Chronic lymphocytic leukaemia16 recruiting
Crohn's disease15 recruiting
Ulcerative colitis13 recruiting
Acute lymphoblastic leukaemia12 recruiting
Metastatic breast cancer12 recruiting
Liver and biliary tract cancer11 recruiting
Gastric and oesophageal cancer9 recruiting
Prostate cancer9 recruiting
ALS (motor neurone disease)8 recruiting
Multiple myeloma8 recruiting
Myelodysplastic syndromes8 recruiting
Bladder cancer7 recruiting
Macular degeneration7 recruiting
Ovarian cancer7 recruiting
Chronic myeloid leukaemia6 recruiting
Endometrial cancer6 recruiting
Lung cancer6 recruiting
Multiple sclerosis6 recruiting
Diffuse large B-cell lymphoma5 recruiting
Follicular lymphoma5 recruiting
Huntington's disease5 recruiting
Alzheimer disease4 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)4 recruiting
Mantle cell lymphoma4 recruiting
Myeloproliferative neoplasms4 recruiting
Stroke4 recruiting
Aortic stenosis3 recruiting
Epilepsy3 recruiting
Head and neck cancer3 recruiting
High blood pressure3 recruiting
Hodgkin lymphoma3 recruiting
Parkinson disease3 recruiting
Atrial fibrillation2 recruiting
Chronic kidney disease2 recruiting
Coronary artery disease2 recruiting
Kidney cancer2 recruiting
Melanoma2 recruiting
Sarcoma2 recruiting
Triple-negative breast cancer2 recruiting
Aortic aneurysm1 recruiting
Coeliac disease1 recruiting
Dermatomyositis and polymyositis (myositis)1 recruiting
Duchenne muscular dystrophy1 recruiting
Gestational diabetes1 recruiting
Graves' disease1 recruiting
Heart failure1 recruiting
HIV1 recruiting
Mild cognitive impairment1 recruiting
Multiple system atrophy1 recruiting
Myasthenia gravis1 recruiting
Myocarditis1 recruiting
Neuroblastoma1 recruiting
Obesity1 recruiting
Osteonecrosis (avascular necrosis)1 recruiting
Pompe disease1 recruiting
Spinal muscular atrophy1 recruiting
Testicular cancer1 recruiting
Thalassaemia1 recruiting
Thyroid cancer1 recruiting
Type 1 diabetes1 recruiting
Type 2 diabetes1 recruiting
Vascular dementia1 recruiting

Closed trials

Completed
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· Phase 2· Novartis Pharma AG· Source
Active, not recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
NCT07246941· Phase 1· Hoffmann-La Roche· Source
Completed
A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)
NCT06453668· Phase 1· Itb-Med AB· Source
Active, not recruiting
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
NCT06975722· Phase 2· Sanofi· Source
Completed
A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis
NCT06867094· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Completed
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
NCT06685718· Phase 1· BeOne Medicines AG· Source
Completed
A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with High-Risk Bladder Cancer Unresponsive to BCG Treatment
2024-515410-41-00· Phase 1/2· F. Hoffmann-La Roche AG· Source
Recruiting
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures
2024-514499-42-00· Phase 3· Neuraxpharm Pharmaceuticals S.L.· Source
Completed
A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML
NCT06563804· Phase 1/2· Institut De Recherches Internationales Servier IRIS· Source
Active, not recruiting
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220· Phase 1· AbbVie· Source
Completed
Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE
NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Active, not recruiting
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
NCT06614192· Phase 2· AbbVie· Source
Completed
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
NCT06667414· Hoffmann-La Roche· Source
Active, not recruiting
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197· Phase 2· AstraZeneca· Source
Completed
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis
2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· Phase 3· Amgen· Source
Completed
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
NCT06430671· Phase 1· Cellerys AG· Source
Completed
A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1
NCT05870748· Phase 2· Sutro Biopharma Inc.· Source
Completed
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis
2023-506655-19-00· Phase 2· Genentech Inc.· Source
Active, not recruiting
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
NCT06216158· Phase 3· University of Heidelberg Medical Center· Source
Active, not recruiting
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875· Phase 2· AbbVie· Source
Completed
The PROTEMBO Trial
NCT05873816· Protembis GmbH· Source
Completed
A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
2022-502457-34-00· Phase 2· F. Hoffmann-La Roche AG· Source
Completed
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source
Completed
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
NCT06182085· Phase 2· PRInnovation GmbH· Source
Withdrawn
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
NCT05743270· Phase 2· Replimune, Inc.· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· Phase 2· Pfizer· Source
Terminated
Continuation Study for Latozinemab
NCT06111014· Phase 3· Alector Inc.· Source
Terminated
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
NCT06139328· Phase 2· Boehringer Ingelheim· Source
Completed
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· Phase 2· Prinnovation GmbH· Source
Completed
A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.
2022-502789-26-01· Phase 2· Agomab Spain S.L.U.· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806· Phase 3· Celgene· Source
Completed
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
NCT06390059· Phase 2· NovoCure Ltd.· Source
Completed
STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
NCT05843578· Phase 2· Agomab Spain S.L.U.· Source
Active, not recruiting
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
NCT05910528· Phase 2· Hoffmann-La Roche· Source
Completed
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT05672199· Phase 2· Amgen Inc.· Source
Completed
Safety and Efficacy of the Olympus CADe System in Real-time Colonoscopy
NCT05943288· Olympus Europe SE & Co. KG· Source
Completed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501· Phase 2· Hoffmann-La Roche· Source
Completed
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
NCT05804032· Phase 3· University of Heidelberg Medical Center· Source
Completed
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)
2022-501261-46-00· Phase 2· Kite Pharma Inc.· Source
Completed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
2023-505816-39-00· Phase 2· F. Hoffmann-La Roche AG· Source
Completed
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)
NCT05675319· Phase 3· University Medical Center Hamburg-Eppendorf· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)
NCT05349721· Phase 2· PTC Therapeutics Inc.· Source
Active, not recruiting
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551· Phase 2· Hoffmann-La Roche· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Bayer· Source
Completed
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216· Phase 3· Abivax S.A.· Source
Completed
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
NCT05512377· Phase 2· Boehringer Ingelheim· Source
Active, not recruiting
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843· Phase 2· Sanofi· Source
Completed
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

Showing 50 of 172.

Registry name variants (74)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Universitaetsklinikum Ulm AoR
Ulm, Baden-Wurttemberg 89081
398 trials
Universitätsklinikum Ulm
Ulm, 89081
82 trials
Universitaetsklinikum Ulm
Ulm, 89081
26 trials
Universitatsklinikum Ulm AöR
Ulm, 89081
15 trials
University Hospital Ulm
Ulm, 89081
15 trials
Ulm University Hospital
Ulm, Baden-Wurttemberg 89070
6 trials
University Hospital Of Ulm AöR
Ulm, 89081
4 trials
University Hospital Of Ulm, Universitatsklinikum Ulm
Ulm, Baden-Wurttemberg 89081
2 trials
- NCT06821542A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
- NCT06585774A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Department of Cardiothoracic and Vascular Surgery, Ulm University Hospital
Ulm, 89081
1 trial
- NCT05487612MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)
  Contact: Georgios Papazisis, Assoc. Prof.
Department of General and Visceral Surgery, University Hospital Ulm
Ulm, 89081
1 trial
- NCT06801899ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
  Contact: Prof. Dr. med. Emrullah Birgin
Department of Ophthalmology, University Hospital Ulm
Ulm, 89075
1 trial
- NCT07531927Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
  Contact: Armin Wolf, Prof. Dr. (principal investigator)
Hospital of University of Ulm
Ulm
1 trial
- NCT05475483Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Ulm Universitätsklinikum
Ulm, 89081
1 trial
- NCT05873816The PROTEMBO Trial
Universitaetsklinikum Ulm AoeR
Ulm, 89081
1 trial
- 2022-501119-14-01Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis
Universitaetsklinikum Ulm /ID# 135230
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Universitaetsklinikum Ulm /ID# 148444
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT02130362A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
Universitaetsklinikum Ulm /ID# 153054
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT02993523A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Universitaetsklinikum Ulm /ID# 215405
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT04379050Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
Universitaetsklinikum Ulm /ID# 253742
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT05753501Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Universitaetsklinikum Ulm /ID# 283884
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT07728188A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Universitaetsklinikum Ulm /ID# 98202
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Universitaetsklinikum Ulm (Site 0267)
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Universitaetsklinikum Ulm (Site 0500)
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT04456699Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
Universitaetsklinikum Ulm. (Site 0902)
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Universitaetsklinikum Ulm. (Site 0906)
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT04728893Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
  Contact: Study Coordinator
Universitaetsklinikum Ulm (Site 2102)
Ulm, Baden-Wurttemberg 89075
1 trial
- NCT04199104A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Universitaetsklinikum Ulm. (Site 2206)
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT05947851A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
  Contact: Study Coordinator
Universitätsklinikum Ulm
Günzburg, 89312
1 trial
- NCT04734444SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue
Universitatsklinikum Ulm AöR (University of Ulm)
Ulm, 89081
1 trial
- NCT05843578STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Universitätsklinikum Ulm / Augenklinik
Ulm, 89070
1 trial
- NCT05269680STAR-LIFE: a Post-market Registry on MINIject
Universitätsklinikum Ulm, Institut für Allgemeinmedizin
Ulm, 89081
1 trial
- NCT07476040Improved Management of Patients With Recent-Onset Stable Chest Pain
  Contact: Anne Barzel, Prof. Dr.
Universitätsklinikum Ulm, Klink für Innere Medizin I
Ulm, 89081
1 trial
- NCT05652348Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer
  Contact: Thomas Seufferlein, Prof. Dr.
Universitätsklinikum Ulm - Leimgrubenweg 12-14
Ulm, 89075
1 trial
- NCT06111014Continuation Study for Latozinemab
Universitätsklinikum Ulm, Universitätsfrauenklinik
Ulm, 89075
1 trial
- NCT03438474Endometrial Cancer Lymphadenectomy Trial
  Contact: Fabienne Schochter, MD
Universitatsklinikum Ulm (University Hospital Ulm)
Ulm
1 trial
- NCT06557798REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Universitätsklinikum Ulm, Zentrum für Innere Medizin I
Ulm, 89081
1 trial
- 2025-525157-39-00SIL204-SL Treatment for Locally Advanced Pancreatic Cancer
Universitatsklinikum Ulm, Zentrum fur Innere Medizin, Innere Medizin III
Ulm, 89081
1 trial
- NCT04778397Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
University Hospital of Ulm
Ulm, 89081
1 trial
- NCT01252485Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
  Contact: Hartmut Döhner, Prof. Dr.
University Hospital of Ulm, Department of Internal Medicine III
Ulm, 89081
1 trial
- NCT02576496Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
University Hospital Ulm -Department of Gynecology
Ulm, Baden-Wurttemberg 89075
1 trial
- NCT02035813DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
University Hospital Ulm, Department of Neurology, Germany
Ulm, Baden-Wurttemberg 89081
1 trial
- NCT07611136Cerebral Small Vessel Disease Progression Dependent on Stroke Type
  Contact: Mona E Laible, MD
University Hospital Ulm, Dept. of Neurology
Ulm, 89081
1 trial
- NCT07897760Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
  Contact: Hayrettin Tumani, Prof. Dr. med.
Department of Cardiology, University Hospital Ulm
Ulm
Ulm University Hospital, Centre for Internal Medicine I
Ulm, 89081
Universitaetsklinikum Ulm /ID# 164990
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 164994
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 203554
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 223400
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 230164
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 244265
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 257783
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 258616
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 262494
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 263148
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 266962
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 269686
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 273411
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm /ID# 280004
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm, Innere Medizin Iii
Ulm, 89081
Universitaetsklinikum Ulm. (Site 0402)
Ulm, Baden-Wurttemberg 89075
Universitaetsklinikum Ulm. (Site 0404)
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm. (Site 0502)
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm. (Site 0530)
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm. (Site 0601)
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm (Site # 0702)
Ulm, 89075
Universitaetsklinikum Ulm. (Site 0994)
Ulm, Bavaria 89081
Universitaetsklinikum Ulm. (Site 1106)
Ulm, Baden-Wurttemberg 89081
Universitaetsklinikum Ulm. (Site 1324)
Ulm, Baden-Wurttemberg 89081
Universitatsklinikum Ulm, Augenklinik und Poliklinik
Ulm, 89075
Universitätsklinikum Ulm, Frauenheilunde und Geburtshilfe
Ulm
Universitätsklinikum Ulm - Innere Med. I
Ulm, 89081
Universitätsklinikum Ulm - Neurologie
Ulm, 89081
Universitatsklinikum Ulm - Standort Oberer Eselsberg
Ulm, 89081
University Hospital Ulm, Otolaryngology & Head and Neck Surgery
Ulm, Baden-Wurttemberg 89070

Conditions

Diseases this institution publishes on or runs trials for.

Acute myeloid leukaemia32 works · 31 trials
Huntington's disease29 works · 11 trials
Bladder cancer29 works · 13 trials
ALS (motor neurone disease)19 works · 17 trials
Head and neck cancer12 works · 16 trials
Chronic lymphocytic leukaemia8 works · 27 trials
Frontotemporal dementia7 works · 2 trials
Aplastic anaemia4 works · 1 trial

Institution data: ROR 05emabm63 (CC0-1.0)Updated 14 Nov 2026

Report an error